WINT Windtree Therapeutics: Accounting Value per Share

Windtree Therapeutics develops cardiology treatments where business scaling relies on patent protection and future manufacturing outsourcing. High barriers to entry are driven by the complexity of certifying drugs for critical conditions. The history of book value per share demonstrates capital dynamics, while 0.39 expresses the current value of the metric. The team consists of a tight-knit circle of scientists motivated by stock options.

This metric is calculated as the difference between total assets and liabilities divided by the number of shares, which determines the intrinsic value of an investor's stake. For Windtree Therapeutics (WINT), the book value per share indicator confirms the efficiency of cost management for cardiovascular drug development, demonstrating how patent protection and financial discipline translate into real growth of equity.